PCMTD1

Across TCGA pan-cancer cohorts, PCMTD1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated PCMTD1 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PCMTD1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PCMTD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and HNSC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where PCMTD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	IV	0.123	0.785	.009	23	view →
UCEC	OS	Tertile	III,IV	0.314	1.000	.022	20	view →
PDAC	DFS	Quartile	III,IV	0.651	0.189	.017	10	view →
HNSC	DFS	Median	III,IV	0.859	0.705	.035	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

PCMTD1–CCRCC (OS)

Open the CCRCC breakdown →